In vitro long-term treatment with MAPK inhibitors induces melanoma cells with resistance plasticity to inhibitors while retaining sensitivity to CD8 T cells

The development of BRAF V600 and MEK inhibitors constitutes a breakthrough in the treatment of patients with BRAF-mutated metastatic melanoma. However, although there is an increase in overall survival, these patients generally confront recurrence, and several resistance mechanisms have already been...

Descripción completa

Detalles Bibliográficos
Autores principales: Rowdo, Florencia Paula Madorsky, Barón, Antonela, Von Euw, Erika María, Mordoh, José
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2017
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5364845/
https://www.ncbi.nlm.nih.gov/pubmed/28098866
http://dx.doi.org/10.3892/or.2017.5363

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5364845/
https://www.ncbi.nlm.nih.gov/pubmed/28098866
http://dx.doi.org/10.3892/or.2017.5363

Ejemplares similares